# Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

> **NCT05687357** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 140 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal-junction Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** S-1
- **DRUG:** Oxaliplatin
- **DRUG:** Nab paclitaxel
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT05687357
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687357, "Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05687357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*